Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
Background. Checkpoint inhibitors are effective in the treatment of several types of cancer, either being used separately or in combination. Ipilimumab pioneered the treatment of metastatic melanoma, and nowadays, it has been used more frequently in combination with anti-PD-1. Since the development...
Saved in:
Main Authors: | A. A. Formozo, J. R. Gomes, R. A. Schmerling, A. C. Buzaid |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Journal of Skin Cancer |
Online Access: | http://dx.doi.org/10.1155/2021/5531864 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
by: Bartosz Chmielowski
Published: (2013-01-01) -
Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
by: Gérald E. Piérard, et al.
Published: (2012-01-01) -
Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01) -
Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
by: Tetsuya Danno, et al.
Published: (2021-01-01) -
Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
by: Anne Rogiers, et al.
Published: (2020-01-01)